Sarah Hussain, MD
Cardiovascular Disease · Hershey, PANPI 1043477615
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (48.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Medtronic at 39.1% of the total. Reporting peaked in 2019 at $27,505 and has fallen 58.4% since, to $11,453 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $213.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$23K
- Boston Scientific$21K
- Acutus Medical, Inc.$12K
- Abbott$2K
- Biosense Webster, Inc.$151
- Johnson & Johnson$107
- plus $120 from 3 others
Across 13 payments — averaging $3139.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$29K
- Boston Scientific$12K
What the payments were for
- Consulting fees$10,20017%
- Speaking & faculty fees$7,51913%
- Travel & lodging$28,50649%
- Food & beverage$12,40421%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 156 | $22,948 |
| Boston Scientific | 57 | $21,289 |
| Acutus Medical, Inc. | 14 | $12,198 |
| Abbott | 20 | $1,878 |
| Biosense Webster, Inc. | 24 | $151 |
| Johnson & Johnson | 1 | $107 |
| Cvrx, Inc. | 1 | $73 |
| AbbVie | 1 | $24 |
| Biotronik Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL EP$7,500
- Watchman$4,947
- Farapulse$3,128
- Arctic Front$2,170
- Micra$1,933
- Performa$1,421
- GENERAL - THERAPIES$1,244
- AVEIR$883
- Azure$630
- SelectSecure$570
- LINQ II$399
- COBALT DR MRI SURESCAN$300
- WATCHMAN Access System$233
- WATCHMAN FLX$174
- NA$172
- Claria MRI$171
- Ensite Cardiac Mapping System$147
- Reveal LINQ$108
- XARELTO$107
- GENERAL PAIN MANAGEMENT$104
How this compares
$58,690 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $165,079 |
| XareltoRivaroxaban | 58 | $64,948 |
| MultaqDronedarone Hcl | 15 | $31,094 |
| Dofetilide | 20 | $7,128 |
| Flecainide Acetate | 48 | $2,137 |
| Metoprolol Succinate | 111 | $1,812 |
| Amiodarone Hcl | 119 | $1,282 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 27 | $782 |
| Digoxin | 23 | $463 |
| Metoprolol Tartrate | 33 | $257 |
| Carvedilol | 25 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $107 | $64,94858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Hershey
- Gerald NaccarelliHershey$155K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.